
In this column, Katherine Saunders, MD, of Weill Cornell Medicine, provides perspective on the approval of tirzepatide for chronic weight management and what it might mean for patient access in the future.

By Katherine H. Saunders, MD, DABOM, Co-Founder of Intellihealth and Clinical Assistant Professor of Medicine at Weill Cornell Medicine.